New Federal Bill Aims to Establish VA Office of Novel Therapeutics
The Veterans Health Administration Novel Therapeutics Preparedness Act is the fourth psychedelics-related bill filed in Congress this term as related legislation gains momentum.
Produced in Partnership with our Friends at Lucid News
By Jack Gorsline
Amid a burgeoning mental health crisis among the nation’s veterans, federal lawmakers and prominent psychedelic advocates alike are escalating a bipartisan push to integrate emerging, once-taboo treatments into the country’s largest integrated healthcare system.
This week, Sen. Tim Sheehy, (R-Montana), a former Navy SEAL, is set to introduce the “Veterans Health Administration Novel Therapeutics Preparedness Act,” a sweeping piece of legislation that seeks to establish a dedicated Office of Novel Therapeutics within the Department of Veterans Affairs. The proposed office would serve as the central coordinating authority for the evaluation, research, and implementation of emerging mental health treatments, specifically focusing on psychedelic-assisted therapies.
The introduction of the new bill marks a significant escalation in the ongoing bipartisan effort to both reshape veteran mental healthcare and expand research into the therapeutic benefits of psychedelics. However, integrating these complex treatments into the sprawling Veterans Health Administration requires navigating a labyrinth of clinical, regulatory, and infrastructural hurdles.
The Office of Novel Therapeutics is explicitly designed to address these roadblocks, aiming to ensure that the VA is not caught flat-footed when and if the U.S. Food and Drug Administration (FDA) formally approves these treatments. The legislation outlines a comprehensive framework to responsibly evaluate and deploy these modalities, balancing the urgent demand for novel therapies with rigorous patient safety and evidence-based clinical practices.
Amy Rising, a Washington, D.C.-based Veteran Mental Healthcare Advocate who was instrumental in the drafting of the new bill, told Lucid News that the introduction of this particular legislative framework, “reflects a growing alignment across the Senate that we can’t afford to wait until these therapies arrive to start preparing for them.”
“Over the past year,” said Rising, “there’s been a quiet but meaningful effort to bring together the right voices - clinicians, veterans, researchers, and policymakers - to think through what responsible implementation actually looks like.”
“This bill is the result of those conversations finally taking shape in a coordinated way. It ensures the VA is ready to lead, not follow, when it comes to delivering next-generation care to veterans.”
Establishing the Office of Novel Therapeutics: Policy, Preparedness, and Patient Care
If enacted, the bill would require the Department of Veterans Affairs to establish an Office of Novel Therapeutics. The office would be responsible for developing national clinical standards, readiness plans, and workforce credentialing frameworks for administering new psychological modalities. The legislation also creates a Clinical Implementation Program to evaluate care delivery models for veterans with severe mental health conditions.
The bill distinguishes psychedelic-assisted therapy from traditional psychiatric medication management, noting that the treatment requires a specialized clinical model rather than simple prescription. Under the proposal, the office must develop a national clinical framework for intensive interventions, including structured psychological preparation, monitored substance administration, and post-administration integration sessions. To support this model, the legislation authorizes the VA to designate specific medical centers as “centers of excellence.” These facilities would lead clinical research, provide hands-on training for VA staff, and serve as hubs for sharing best practices.
“There’s real progress happening in Congress right now, and this bill is part of that shift, from research to readiness,” said Melissa Lavasani, founder of the Psychedelic Medicine Coalition. “For veterans, it means earlier access within the VA. For everyone else, it helps establish the model for how these treatments can be delivered safely at scale.”
The bill also aims to reduce bureaucratic barriers by requiring the office to establish patient candidacy guidance. This would prevent “step therapy” or “fail-first” protocols – which require patients to try older or less expensive treatments before accessing newer ones – from restricting access to novel therapeutics when they are clinically appropriate.
The legislation mandates the formation of a Veteran Advisory Committee to provide guidance on patient safety, informed consent in altered states of consciousness, and barriers to access. Additionally, the new office would coordinate with federal agencies, including the U.S. Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and the Centers for Medicare and Medicaid Services (CMS), to manage drug rescheduling and reimbursement frameworks. The VA would be required to submit a national preparedness strategy to Congress within 180 days of the bill's passage, followed by annual reports on clinical outcomes and safety events.
Bureaucratic Strain, Budget Cuts, and Complex Care Realities at the VA
The ambitious legislative push to create a new, highly specialized bureaucratic infrastructure at the VA arrives at an exceptionally complicated and precarious time for government-funded veteran care. The reality on the ground at VA medical centers stands in stark contrast to the optimistic clinical models proposed in Washington. Recent reporting by ProPublica has meticulously documented the severe, systemic impact of deep government spending cuts implemented under the Trump administration’s Department of Government Efficiency (DOGE).
Since the beginning of the current administration's term, the VA has reportedly lost hundreds of specialized mental health professionals due to budget reductions, hiring freezes, and attrition. Implementing a resource-intensive treatment model like psychedelic-assisted therapy – which routinely requires two trained therapists to monitor a single patient for up to eight hours at a time – presents a monumental logistical challenge for an agency currently struggling to maintain basic, routine psychiatric services.
A Crowded Legislative Field and (Some) Stalled Efforts on Capitol Hill
This new legislation is not emerging in a vacuum; it is part of a broader, though occasionally stumbling, congressional movement regarding psychedelic policy reform. In December 2025, Sens. Cory Booker, (D-N.J)., and Rand Paul, (R-KY), introduced the Freedom to Heal Act. This bipartisan proposal was designed to significantly expand the federal Right to Try law passed in 2018.
The Booker-Paul legislation proposed granting eligible patients with life-threatening conditions legally protected access to certain experimental drugs that have not yet been approved by the FDA – specifically targeting Schedule I substances under DEA jurisdiction, such as psilocybin, ibogaine, and MDMA, provided they have successfully undergone at least one round of Phase I clinical trials.
Despite securing high-profile endorsements from prominent psychedelic research organizations and national veteran advocacy groups, the Freedom to Heal Act currently appears unlikely to advance out of committee. In February, reporting by DoubleBlind Magazine, revealed leaked email correspondence from within the Senate Veterans' Affairs Committee indicating that the bill fundamentally lacks the necessary support from key committee members to move to a floor vote.
Earlier this month, a third major piece of psychedelics-focused federal legislation – the “Innovative Therapies Centers for Excellence Act of 2026” (S.4031) along with its House companion bill (HR 2623) – was announced by Sens. Ruben Gallego, D-Ariz., and Rob McCormick, R-Pa. The introduction of this legislation closely followed a landmark November 2025 announcement by the VA, which confirmed that nine regional facilities – including major medical centers located in Los Angeles, San Diego, and the Bronx in New York City – are already actively participating in multi-year clinical studies on psychedelic compounds.
Possibly muddying the tides of progress further, a cloud of ethical and legal uncertainty currently hangs over these legislative maneuvers. Further reporting by DoubleBlind Magazine earlier this month revealed that last year, the Office of Congressional Conduct (OCC) and the United States Department of Justice (DOJ) received two separate, respective complaints alleging potentially illegal lobbying activity involving former Congresswoman Mimi Walters, her organization the Association for Prescription Psychedelics (APP), and former Senator Kyrsten Sinema.
As lawmakers continue to voice support for forward-thinking federal legislation aimed at revolutionizing PTSD and TBI treatments, the profound disconnect between Capitol Hill's legislative aspirations and the VA's current operational and ethical realities continues to widen. However, advocates remain optimistic about the broader legislative momentum regarding veterans' health.
"Senator Sheehy's introduction of this legislation is a sign that Congress hasn't lost sight of this issue," said Logan Davidson, policy director for Veterans Exploring Treatment Solutions (VETS). "He served this country in uniform, and that lived experience brings a level of credibility and urgency to this conversation that matters. He knows personally what's at stake. At a time when Washington is pulled in countless directions, the fact that this remains front and center is encouraging. Expanding access for veterans is a critical priority, and building the infrastructure to do that responsibly is exactly the kind of forward-thinking approach this moment calls for."
Whether the proposed Office of Novel Therapeutics can successfully bridge the gap between cutting-edge clinical science and a severely strained federal health care system remains one of the most critical questions facing the future of mental health care for veterans.
